Artios

Artios Pharma is a biotechnology company focused on DNA damage response for cancer treatment, developing first-in-class therapies

Biotech & Life Sciences

Sector

Seed

Stage

Biotechnology

Model

01Company Overview

Artios Pharma is a biotechnology company focused on DNA damage response for cancer treatment, developing first-in-class therapies.

02Backed By1 investor

03Recent Activity

Startup Intelligence by F4F4 Research Engine

Artios dosed the first patient in its randomized Phase 2 POLKA study of DNA polymerase theta inhibitor ART6043 in breast cancer.

MILESTONE·m-ventures.com

MAY 26, 2026

Artios' randomized Phase 2a study of low-dose alnodesertib plus gemcitabine achieved its primary endpoint in platinum-resistant ovarian cancer.

MILESTONE·m-ventures.com

MAR 2, 2026

04Similar Companies

AP

BT

BR

AT

RM

05Startup DNA

signals

Sectors
Business Model
Technology

Quick Reference

Sector

Biotech & Life Sciences · Healthcare & Digital Health